Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115384 · ClinicalTrials.gov registry record · Phase 2
Intranasal Insulin in Frontotemporal Dementia (FTD)
A Phase 2 study, sponsored by HealthPartners Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04115384 is a Phase 2 study that was terminated before completion, run by HealthPartners Institute. The registered enrollment target is 3 participants.
The verdict
NCT04115384, a Phase 2 study, was terminated before completion, sponsored by HealthPartners Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the ability of the HealthPartners Center for Memory and Aging's ability to sufficiently recruit subjects with FTD, and the safety of IN regular insulin administered 20 IU twice per day in two specific variants of FTD (behavioral variant frontotemporal dementia (bv-FTD), semantic dementia (SD)) over a 4 week period.
Interventions
- DRUG Novolin-R insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04115384
The ClinicalTrials.gov registry entry for NCT04115384 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novolin-R insulin is the first listed.
NCT04115384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04115384 about?
NCT04115384 is a clinical study titled "Intranasal Insulin in Frontotemporal Dementia (FTD)". This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the ability of the HealthPartners Center for Memory and Aging's ability to suf...
What is the current status of trial NCT04115384?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-09-09. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT04115384?
The interventions under investigation include: Novolin-R insulin (DRUG).
Who is sponsoring clinical trial NCT04115384?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.